🔎 Trials Near Me

Gara Jalqabaatti › Leukemia Myeloidii Hamaa › California › Los Angeles

Qorannoo klinikaalii Leukemia Myeloidii Hamaa Los Angeles, CA keessatti

Qorannoo 24 Leukemia Myeloidii Hamaa f Los Angeles fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.

Takkalaa qorannoo (Ingiliffa)

Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Namoota walitti qabaa jiraSadarkaa 2
  • Cedars-Sinai Medical Center, Los Angeles
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 05-Onk-2026 · NCT05564390

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Namoota walitti qabaa jiraSadarkaa 2
  • Cedars-Sinai Medical Center, Los Angeles
Umuriin 18 hanga 59 · Saalaa hunda · Haaromfame 28-Ful-2026 · NCT05554393

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

Namoota walitti qabaa jiraSadarkaa 2
  • Cedars-Sinai Medical Center, Los Angeles
Umuriin 18 hanga 59 · Saalaa hunda · Haaromfame 22-Ful-2026 · NCT05554406

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Namoota walitti qabaa jiraSadarkaa 2
  • Cedars-Sinai Medical Center, Los Angeles
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 22-Ful-2026 · NCT06317649

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Namoota walitti qabaa jiraSadarkaa 3
  • Children's Hospital Los Angeles, Los Angeles
  • Cedars-Sinai Medical Center, Los Angeles
  • Mattel Children's Hospital UCLA, Los Angeles
6 Months – 21 Years · Saalaa hunda · Haaromfame 17-Ful-2026 · NCT04293562

Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

Namoota walitti qabaa jiraSadarkaa 2
  • USC Norris Comprehensive Cancer Center, Los Angeles
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 16-Ful-2026 · NCT06824168

(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

Namoota walitti qabaa jiraSadarkaa 2
  • UCLA Medical Center, Los Angeles
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 15-Ful-2026 · NCT04996875

Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

Namoota walitti qabaa jiraSadarkaa 3
  • US-Los Angeles CA-UCLA, Los Angeles
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 02-Ful-2026 · NCT06652438

Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

Namoota walitti qabaa jiraSadarkaa 3
  • US-Los Angeles CA-UCLA, Los Angeles
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 01-Ful-2026 · NCT07223814

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Namoota walitti qabaa jiraSadarkaa 3
  • Cedars-Sinai Medical Center, Los Angeles
  • University of California, Los Angeles, Los Angeles
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 20-Hag-2026 · NCT07007312

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Namoota walitti qabaa jiraSadarkaa 1
  • USC Norris Comprehensive Cancer Center, Los Angeles
  • UCLA Health - Bowyer Oncology Center, Los Angeles
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 20-Hag-2026 · NCT06001788

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

Namoota walitti qabaa jiraSadarkaa 3
  • University of California Los Angeles (UCLA) - David Geffen School of Medicine, Los Angeles
Umuriin 18 hanga 75 · Saalaa hunda · Haaromfame 17-Ado-2026 · NCT05429632

Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Namoota walitti qabaa jiraSadarkaa 2
  • UCLA Department of Medicine, Los Angeles
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 07-Ado-2026 · NCT07216443

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Namoota walitti qabaa jiraQorannoo ilaalaa
  • UCLA, Los Angeles
Umuriin hundi · Saalaa hunda · Haaromfame 06-Ado-2026 · NCT01351545

Characterization of T-cell Repertoire in Patients With Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant

Namoota walitti qabaa jiraQorannoo ilaalaa
  • USC / Norris Comprehensive Cancer Center, Los Angeles
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 03-Wax-2026 · NCT03921047

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Namoota walitti qabaa jiraSadarkaa 2/3
  • Keck School of Medicine of USC, Los Angeles
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 30-Elb-2026 · NCT04256317

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Namoota walitti qabaa jiraSadarkaa 1
  • USC / Norris Comprehensive Cancer Center, Los Angeles
  • UCLA - Bowyer Oncology Center, Los Angeles
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 13-Bit-2026 · NCT05735184

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Namoota walitti qabaa jiraSadarkaa 1
  • UCLA, Los Angeles
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 16-Ama-2026 · NCT05143996

A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

Namoota walitti qabaa jiraSadarkaa 1
  • University of California Los Angeles, Los Angeles
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 24-Ful-2025 · NCT06501196

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Namoota walitti qabaa jiraSadarkaa 1/2
  • USC/Norris Comprehensive Cancer Center, Los Angeles
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 26-Hag-2025 · NCT03850574

A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)

Namoota walitti qabaa jiraSadarkaa 1
  • UCLA Medical Center, Los Angeles
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 10-Bit-2025 · NCT05190471

Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML

Namoota walitti qabaa jiraSadarkaa 2
  • UCLA Medical Center, Los Angeles
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 07-Bit-2025 · NCT02781883

Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure

Namoota walitti qabaa jiraSadarkaa 2
  • UCLA / Jonsson Comprehensive Cancer Center, Los Angeles
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 29-Cam-2024 · NCT04905810

Qorannoo Leukemia Myeloidii Hamaa magaalota biroo keessatti

Qorannoo biroo Los Angeles keessatti

Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.